A. Szumski

发表

Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo

B. Rothbaum, D. Stein, J. Davidson, 2012, Journal of psychopharmacology.

Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials

D. Collier, H. Jones, A. Koenig, 2015, The Journal of Rheumatology.

The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis.

H. Jones, A. Koenig, X. Baraliakos, 2019, Seminars in arthritis and rheumatism.

Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies

D. Zack, A. Koenig, I. E. van der Horst-Bruinsma, 2012, Annals of the rheumatic diseases.

Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study

M. Brown, M. Dougados, P. Mease, 2017, Annals of the Rheumatic Diseases.

Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial

L. Kemény, E. Aldinc, W‐R. Lee, 2015, BMC Dermatology.

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis

P. Emery, Yoshiya Tanaka, J. Smolen, 2019, Arthritis Research & Therapy.

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

J. Smolen, A. Koenig, T. Jones, 2018, Arthritis Research & Therapy.

Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis

C. Griffiths, H. Jones, E. Christophers, 2015, The British journal of dermatology.

Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.

P. Mease, J. Smolen, P. Nash, 2022, Seminars in arthritis and rheumatism.

Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value

A. Gottlieb, L. Coates, J. Merola, 2018, The Journal of Rheumatology.

Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis

L. Puig, T. Tsai, A. Koenig, 2015, The Journal of dermatological treatment.

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

K. Pavelka, P. Miranda, J. Smolen, 2013, The Lancet.

Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia

S. Kotak, R. Burgos-Vargas, Khalid Shirazy, 2016, Rheumatology International.

Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR

M. Dougados, D. M. van der Heijde, R. Landewé, 2021, Arthritis Research & Therapy.

Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis

M. Dougados, H. Jones, W. Maksymowych, 2017, Annals of the rheumatic diseases.

Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis

M. Dougados, D. M. van der Heijde, I. Logeart, 2017, Annals of the rheumatic diseases.

How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?

D. M. van der Heijde, A. Koenig, R. Fleischmann, 2014, Annals of the rheumatic diseases.

Evaluation of whether extremely high enthesitis or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores suggest fibromyalgia and confound the anti-TNF response in early non-radiographic axial spondyloarthritis.

M. Dougados, I. Logeart, H. Jones, 2017, Clinical and experimental rheumatology.

MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation

M. Dougados, H. Jones, W. Maksymowych, 2017, Arthritis Research & Therapy.

Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.

H. Nab, A. Koenig, R. Fleischmann, 2014, Rheumatology.

DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable

D. M. van der Heijde, P. Gardiner, R. Fleischmann, 2017, RMD Open.

Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial.

J. McMurray, K. Swedberg, M. Böhm, 2020, Journal of hypertension.

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib

P. Nash, V. Azevedo, L. Bessette, 2021, Rheumatology and Therapy.

Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment

A. Koenig, R. Pedersen, D. Robertson, 2014, The Journal of dermatological treatment.

Dietary Total Fat Intake and Ischemic Stroke Risk: The Northern Manhattan Study

R. Sacco, M. Elkind, M. Paik, 2009, Neuroepidemiology.

Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia

Mahboob Rahman, S. Kotak, K. Pavelka, 2014 .

Induction of response with etanercept–methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study

S. Kotak, K. Pavelka, V. Mazurov, 2013, Clinical Rheumatology.

Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.

M. Dougados, D. M. van der Heijde, J. Braun, 2012, Rheumatology.

Does psoriatic axial spondyloarthritis phenotype correlate with imaging morphotype?

L. Gensler, H. Jones, X. Baraliakos, 2019, Clinical and experimental rheumatology.

Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe

L. Kemény, M. Majdan, P. Vítek, 2018, The Journal of dermatological treatment.

A factor analysis of posttraumatic stress disorder symptoms using data pooled from two venlafaxine extended-release clinical trials

B. Rothbaum, D. Stein, J. Davidson, 2013, Brain and behavior.

Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity

V. Strand, S. Kotak, J. Smolen, 2016, Arthritis Research & Therapy.

Clinical, Radiologic, and Functional Outcomes Following Methotrexate Withdrawal in Etanercept-Treated Patients with Active Early Rheumatoid Arthritis: A Subanalysis of COMET Year 2 by Week 52 DAS28 Status

F. Breedveld, P. Emery, A. Szumski, 2021, The Open Rheumatology Journal.

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA

J. Walsh, G. Krueger, H. Jones, 2018, Psoriasis.

Predictors of response to etanercept-methotrexate treatment: a post hoc logistic regression analysis of a randomized, open-label study in Latin American patients with rheumatoid arthritis

R. Xavier, R. Pedersen, C. Pacheco-Tena, 2021, Advances in Rheumatology.

AB0821 Baseline Characteristics of Patients with Moderate to Severe Psoriatic Arthritis: Post-Hoc Analysis of Responders vs Non-Responders to Etanercept

P. Gisondi, G. Girolomoni, H. Jones, 2015 .

Spondyloarthropathies (Including Psoriatic Arthritis) [40–69] 40. Eagle's Syndrome: An Unusual Association with Sero-Negative Arthropathy

L. Coates, D. Gladman, C. May, 2010 .

SAT0461 Characterisation of different low disease activity measurements in patients with psoriatic arthritis

J. Merola, A. Gottlieb, L. Aikman, 2017 .

SAT0441 Comparison of different remission targets in patients with psoriatic arthritis and evaluation of their prognostic value

L. Aikman, A. Szumski, A. Chhabra, 2017 .